SASPase Inhibitors
Chemical inhibitors of SASPase can exert their inhibitory effects through various pathways and mechanisms. For instance, Acarbose disrupts carbohydrate absorption and digestion, and since SASPase is implicated in skin hydration and barrier function, which are influenced by systemic glucose levels, the alteration in glucose metabolism by Acarbose can indirectly lead to SASPase inhibition. Allopurinol, affecting purine metabolism by inhibiting xanthine oxidase, can reduce the availability of nucleotide precursors necessary for SASPase function. Genistein, acting as a kinase inhibitor, can interfere with phosphorylation processes vital for SASPase activation and function. Genistein targets tyrosine kinases that can control SASPase activation state.
In a similar vein, Rapamycin, as an mTOR inhibitor, can modify cell growth and proliferation, leading to changes in the cellular environment that indirectly inhibit SASPase function in skin cells. PD98059 and U0126, both affecting the MAPK/ERK pathway, can alter the differentiation state of keratinocytes, thus reducing SASPase activity. SB203580, inhibiting p38 MAPK, can decrease inflammatory signals that regulate SASPase activity. LY294002, a PI3K inhibitor, can reduce SASPase activity by influencing various cellular functions, including those that may regulate SASPase. Sunitinib and Sorafenib, as inhibitors of receptor tyrosine kinases and RAF kinase, respectively, can alter cellular signals in skin to indirectly inhibit SASPase by affecting the proliferative signals that regulate its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $222.00 $593.00 | 1 | |
Acarbose is an alpha-glucosidase inhibitor that disrupts carbohydrate digestion and absorption. Considering that SASPase is involved in skin barrier function and hydration, which can be influenced by systemic glucose levels and metabolism, Acarbose's role in modifying glucose metabolism could indirectly inhibit SASPase by altering systemic conditions and substrates necessary for its optimal function. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol is an inhibitor of xanthine oxidase and impacts purine metabolism. SASPase, associated with skin barrier function, may require nucleotide precursors for proper function and regulation. By inhibiting purine biosynthesis, Allopurinol could indirectly lead to a reduction in the availability of essential nucleotides, thus potentially inhibiting SASPase activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor and is known to affect cell signaling. Tyrosine phosphorylation can regulate enzyme activity; therefore, Genistein could indirectly inhibit SASPase by interfering with signaling pathways that control its activation state. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and affects cell growth and proliferation. As SASPase is implicated in skin differentiation and barrier function, the inhibition of mTOR signaling by Rapamycin could lead to an altered cellular environment that indirectly inhibits SASPase function in skin cells. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway, a key signaling pathway in cell differentiation. Since SASPase is involved in keratinocyte differentiation, the inhibition of the MAPK/ERK pathway by PD98059 could result in an indirect inhibition of SASPase by altering the differentiation state of the cells where SASPase functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor and affects inflammatory response pathways. Given that SASPase has been implicated in skin inflammation processes, inhibition of p38 MAPK could indirectly inhibit SASPase function by reducing the inflammatory signals that might upregulate its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor and affects a variety of cellular functions including metabolism and survival. Since PI3K signaling can influence various cellular functions that could include the regulation of enzymatic activities like SASPase, its inhibition could result in an indirect reduction of SASPase activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor and has effects on angiogenesis and cell proliferation. By inhibiting tyrosine kinase signaling pathways, SASPase function could be indirectly inhibited because these pathways may be involved in the regulation of cellular processes that support SASPase activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF kinase inhibitor that also impacts several receptor tyrosine kinases associated with cell proliferation and angiogenesis. By altering the signaling environment in cells, particularly in the skin where SASPase is active, Sorafenib could indirectly inhibit SASPase through a reduction in the proliferative signals that might regulate its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a specific inhibitor of MEK1/2, enzymes responsible for the phosphorylation and activation of MAPK/ERK. By inhibiting this pathway, U0126 could indirectly reduce SASPase activity by altering the cellular differentiation processes in keratinocytes where SASPase is known to function. | ||||||